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Chagas disease reactivation has been a deﬁning condition for acquired immune deﬁciency
syndrome in Brazil for individuals coinfected with Trypanosoma cruzi and HIV since 2004.
Although the ﬁrst coinfection case was reported in the 1980s, its prevalence has not been
ﬁrmly established. In order to know coinfection prevalence, a cross-sectional study of 200
HIV  patients was performed between January and July 2013 in the city of Pelotas, in southern
Rio  Grande do Sul, an endemic area for Chagas disease. Ten subjects were found posi-
tive  for T. cruzi infection by chemiluminescence microparticle immunoassay and indirect
immunoﬂuorescence. The survey showed 5% coinfection prevalence among HIV patients
(95% CI: 2.0–8.0), which was 3.8 times as high as that estimated by the Ministry of Health of
Brazil. Six individuals had a viral load higher than 100,000 copies per L, a statistically signif-
icant difference for T. cruzi presence. These ﬁndings highlight the importance of screeningHIV  patients from Chagas disease endemic areas.
©  2016 Published by Elsevier Editora Ltda. on behalf of Sociedade Brasileira de
Infectologia. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
transplant recipients, cancer patients, and individuals living
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32merican trypanosomiasis, also known as Chagas disease
CD), is a neglected tropical condition.1,2 The World Health
rganization estimates that eight million people worldwide
re presently infected with Trypanosoma cruzi.2Please cite this article in press as: Stauffert D, et al. Prevalence of Trypano
http://dx.doi.org/10.1016/j.bjid.2016.10.006
CD chronic infection is characterized by low parasite levels
n the blood and in cardiac and/or digestive tract tissues, which
ypically persists throughout life. The chronic infection may
∗ Corresponding author.
E-mail address: marcos.villela@ufpel.edu.br (M.M. Villela).
ttp://dx.doi.org/10.1016/j.bjid.2016.10.006
413-8670/© 2016 Published by Elsevier Editora Ltda. on behalf of Socied
he  CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nmanifest itself as indeterminate or symptomatic, and 20–30%
of Chagas patients develop cardiomyopathy, megaesophagus,
or megacolon.3 Nevertheless, the disease may seriously affectBJID 669 1–5
soma cruzi/HIV coinfection in southern Brazil. Braz J Infect Dis. 2016.
with AIDS due to immunosuppression.4,5 Indeed, T. cruzi, like
other infectious organisms, is an opportunistic protozoan in
these patients.6,7
ade Brasileira de Infectologia. This is an open access article under
d/4.0/).
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Table 1 – Sociodemographic and behavioral proﬁle of patients surveyed for Trypanosoma cruzi/HIV coinfection in the
extreme south of Brazil. n = 200.
Sociodemographic variable n %
Gender Male  99 49.5
Female 101 50.5
Age Up to 29 41 20.5
30–39 51 25.5
40–49 53 26.5
50+ 55 27.5
Completed years of
education
0–4  49 24.5
5–8 86 43.0
9+ 65 32.5
Marital status Married  105 52.5
Single 76 38.0
Widowed 8 4.0
Divorced 11 5.5
Monthly incomea <1 minimum wage 117 58.5
>1 minimum wage 48 24.0
No wage 35 17.5
Smoking Yes 174 87.0
No 26 13.0
Alcohol
consumption
Every day 3 1.5
>once a week 45 22.5
<once a week 8 4.0
Never 144 72.0
Drug use Yes  26 13.0
No 174 87.0
Antiretroviral
therapy
Yes 143 71.5
No 57 28.5
CD4+ T lymphocytes
(cells mm3)
Up  to 350 51 25.5
>350 149 74.5
Viral load (copies per
L)
<50  146 73.0
51–100,000 40 20.0
>100,000 14 7.0
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Migration from rural to urban areas in Brazil and other Latin
American countries has particularly increased the probability
of individuals with Chagas disease to contract HIV.8,12 Con-
sequently, Chagas disease reactivation in coinfected patients
was declared an Aids-deﬁning condition in 2004; as a con-
sequence, the Brazilian Network of Care and Studies on T.
cruzi/HIV coinfection was created in 2006.8–10 The 2008 Guide-
lines from the Brazilian Ministry of Health10 recommended a
Chagas Disease serological test for all HIV patients, especially
those from endemic areas, at the ﬁrst medical assessment.
In those countries where CD is endemic, the coinfec-
tion HIV/T. cruzi rate ranges from 1.3% to 7.1%,11 whereas in
Brazil the estimate is 1.3%.10 According to data from HIV/AIDS
reports of the Ministry of Health in Brazil, the Southern and
Central-Western regions of the country have the highest num-
ber of reported cases. Among municipalities with more  than
100,000 inhabitants, the city of Pelotas occupies the twenti-
eth position, with 5943 cases.12 In the same municipality, aPlease cite this article in press as: Stauffert D, et al. Prevalence of Trypano
http://dx.doi.org/10.1016/j.bjid.2016.10.006
study of 252 HIV+ patients13 measured the serologic testing
index for Chagas, ﬁnding a 3.2% rate (eight patients), seven
of whom were negative for trypanosomiasis and one had noresults available in his medical record. The authors expressed
concern on the low serologic testing index for CD in HIV+
patients, since the study was conducted in an area considered
to be endemic for the presence of T. cruzi and its vectors.14,15
Given the lack of coinfection data in endemic areas and
the relevance of the topic to public health, the aim of this
study was to evaluate the T. cruzi/HIV coinfection prevalence
in patients cared for at a specialized service center in the city
of Pelotas, Rio Grande do Sul State, Brazil, as well as to eval-
uate coinfection correlation, if any, with gender, age, CD4+ T
lymphocytes, and viral load.
A cross-sectional study was conducted with patients being
monitored at in the Special Care Service (SCS) of the Med-
ical School of the Federal University of Pelotas (UFPEL), Rio
Grande do Sul State, Brazil. This service is a partnership with
the Municipal Health Department of Pelotas, and provides care
to public health system patients. The population under study
comprised of 200 HIV infected patients, characterizing a rep-BJID 669 1–5
soma cruzi/HIV coinfection in southern Brazil. Braz J Infect Dis. 2016.
resentative SCS sample. The age of patients ranged between
18 to 80 years, and included both male and female patients.
The study was performed between January and July 2013.
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Table 2 – Association of Trypanosoma cruzi/HIV coinfection in the extreme south of Brazil with sociodemographic factors,
CD4+ T lymphocytes, and viral load. n = 200, of which 10 were coinfected.
Variable n % p-Valuea Odds ratio (95% CI)b
Age
Up to 29 2 4.9 0.609 1
30–39 1 2.0 0.39 (0.03–4.45)
40–49 4 7.7 1.63  (0.28–9.34)
50+ 3 5.5 1.13  (0.18–7.06)
Gender
Male 6 6.0 0.535 1
Female 4 4.0 0.63 (0.02–2.33)
Completed years of education
0–4 4 8.2 0.461 1
5–8 3 3.5 0.41 (0.09–1.89)
9+ 3 4.6 0.54 (0.11–2.55)
Marital status
Married 6 5.7 0.501 1
Single 2 2.6 0.44 (0.09–2.27)
Widowed 1 12.5 2.35 (0.25–22.4)
Divorced 1 9.1 1.65 (0.18–15.11)
Monthly income
<1 minimum wage 9 6.3 0.287 1
>1 minimum wage 1 1.7 0.26 (0.03–2.09)
CD4+ T lymphocytes (cells/mm3)
Up to 350 6 7.8 0.280 1
>350 4 4.0 0.49 (0.13–1.82)
Viral load (copies per L)
<50 3 4.1 0.027 1
50–100,000 1 2.4 0.58 (0.07–5.00)
>100,000 6 23.1 7.00 (1.5–32.23)
a Fisher’s exact test.
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Socioeconomic, demographic, and behavioral information
as collected according to a pre-tested structured ques-
ionnaire. The following data regarding socioeconomic and
emographic variables were collected: residence in a T. cruzi
ndemic area (yes or no), gender (male or female), age group
up to 29, 30–39, 40–49, 50 years or older), education in school
ears (0–4, 5–8, 9 or more), marital status (married, single, wid-
wed, or divorced), and monthly income (up to one or more
han one minimum wage). The following behavioral variables
ere obtained: smoking, currently or up to the month before
he interview (yes or no); alcohol intake currently or up to the
onth before the interview (less than once a week, more  than
nce a week, every day, or never); current occasional drug use
yes or no). Treatment with antiretroviral therapy (yes or no),
D4+ T lymphocytes (up to 350 or >350 cells/mm3), and viral
oad (<50, 51–100,000, or >100,000 copies/L) were obtained
rom medical records.
Blood samples were collected and tested for anti-T. cruzi
gG at the Clinical Analysis Laboratory of the Federal Univer-
ity of Pelotas. Samples were ﬁrst tested by Chemiluminescent
icroparticle Immunoassay (ARCHITECT Chagas
®
, Abbott).Please cite this article in press as: Stauffert D, et al. Prevalence of Trypano
http://dx.doi.org/10.1016/j.bjid.2016.10.006
ositive results from this test were checked by indirect
mmunoﬂuorescence (WAMA
®
Diagnóstica) according to
anufacturer’s instructions. Samples testing positive onboth assays were considered infected, and test results were
transferred to patient records and made available to both
physicians and patients.
Sociodemographic, anti-T. cruzi IgG, and behavioral factors
were analyzed by descriptive statistics using Stata
®
12 (Stata-
Corp LP, College Station, TX, USA). For analysis of coinfection
against sociodemographic variables, CD4+ T lymphocytes, and
viral load Fisher’s exact test and logistic regression were used
to compare proportions and obtain odds ratios, respectively.
The study was reviewed and approved by the Ethics Com-
mittee of the Medical School of the Federal University of
Pelotas, Brazil according to Resolution 466/12 on research
involving human subjects of the Brazilian National Health
Council. All subjects of this research were adults and were
asked to sign an informed consent after being informed on
the purpose and procedures of the study.
Table 1 shows sociodemographic and behavioral character-
istics of the 200 patients who participated in the study. There
were no refusals by respondents during the research. 49.5%
(99) of the respondents were male and 50.5% (101), female.
Most of the patients (54%) were 40 years of age or older, andBJID 669 1–5
soma cruzi/HIV coinfection in southern Brazil. Braz J Infect Dis. 2016.
43% had 5–8 years of schooling, while 52% were married.
Among those who reported having an income (82.5%), 58.5%
earned up to one minimum wage.  As to behavioral variables,
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87% smoked, 28% had drunk alcohol in the previous month
and 87% had never used illicit drugs. Most patients (71.5%)
were undergoing antiretroviral treatment and 74.5% of the
patients had LT CD4+ count higher than 350 cells/mm3.
Ten individuals tested positive for T. cruzi, corresponding to
5% prevalence (95% CI: 2.0–8.0) among HIV patients. All were
on antiretroviral therapy. The only variable signiﬁcantly dif-
ferent between coinfected and monoinfected patients was the
rate of viral load higher than 100,000 copies per L, as shown
in Table 2.
Of the 200 individuals evaluated in this study, 10 were diag-
nosed with coinfection T. cruzi/HIV (5%), a rate 3.8-fold higher
than the 1.3% estimate by the Ministry of Health in 2013.10
Thus, the survey highlights T. cruzi as a potential opportunis-
tic parasite in HIV patients from areas where Chagas disease
is endemic,16 such as southern Rio Grande do Sul, Brazil. A
survey of HIV/T. cruzi coinfection in Europe in patients from
Bolivia, Argentina, or the Southern Cone, conﬁrmed a 1.9%
coinfection.16 A study in Argentina, a country with the largest
number of reported coinfection cases, along with Brazil,17 the
prevalence of T. cruzi/HIV coinfection was 4.2%, similar to that
in this study.18
High viral loads and a reduction in CD4+ T lymphocytes
can lead to immunosuppression, and may be considered a
reactivation risk factor,19 although there are no reliable meth-
ods of predicting this reactivation. In this study, most patients
were on antiretroviral therapy, which appears to prevent or
control Chagas reactivation.4 Indeed, the 10 coinfected indi-
viduals in this study had no symptoms consistent with Chagas
reactivation. However, these patients need to be monitored
carefully, as mortality may reach 80% if treatment is delayed
for at least 30 days after the onset of Chagas symptoms, while
early treatment reduces it to 20%.9
As to the variables analyzed, there was a statistically
signiﬁcant association only for coinfection and viral load
above 100,000 copies (OR = 7.0). Although such association was
found, one cannot be sure whether it is the T. cruzi parasite that
caused this viral load increase. Nevertheless, evaluations have
shown an association between CD reactivation, the decrease
in CD4+ cell count, and increase in viral load.20 This associa-
tion was not observed in this study, once CD reactivation cases
were not detected. Therefore, other detailed reviews on this
topic are needed.
This coinfection has been poorly characterized, and
remains unknown to or neglected by many  health profes-
sionals. Serological tests for Chagas disease in southern
Brazil were requested at the ﬁrst medical appointment for
only 3.2% of HIV cases, even though the 2013 Consen-
sus Document of the Ministry of Health recommends that
such tests be requested for all HIV patients at the ﬁrst
appointment.10,13
Due to the possibility of the occurrence of both etiolog-
ical agents in the same individual and the likely severity
of this coinfection, it was concluded that the Ministry of
Health guidelines as to the need for T. cruzi serological tests in
HIV+ patients from CD endemic areas are relevant. Our study
showed a coinfection rate 3.8-fold higher than that estimatedPlease cite this article in press as: Stauffert D, et al. Prevalence of Trypano
http://dx.doi.org/10.1016/j.bjid.2016.10.006
for Brazil. Furthermore, patients who have been made aware
of this condition can beneﬁt from specialized medical care,
thus avoiding eventual damage resulting from it.
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